What are the ESTHER Trials?
- A programme of Phase 3 randomised, multinational clinical studies
- Investigating the safety and efficacy of a personalised approach to assisted reproductive technology (ART) for recombinant follicle-stimulating hormone (rFSH) compared with follitropin alfa
- Involving more than 1,326 patients in 11 countries worldwide
- ESTHER-I: Pivotal, Phase 3, non-inferiority trial comparing efficacy and safety of REKOVELLE® vs follitropin alfa in patients undergoing their first cycle of ovarian stimulation.2
- ESTHER-II: Phase 3 trial evaluating the immunogenicity of follitropin delta in patients receiving repeated cycles of ovarian stimulation (cycles 2 and 3) following initial stimulation with REKOVELLE® or follitropin alfa in ESTHER-I.3
LEARN MORE ABOUT THE ESTHER-I CLINICAL TRIAL
LEARN MORE ABOUT THE ESTHER-II CLINICAL TRIAL